Clinical Trial Update: Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial of TRX518, an anti-GITR monoclonal antibody, in unresectable stage III/IV malignant melanoma or other solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Other Solid Tumors

Drugs mentioned

• TRX518

Snippet

Sponsor: Leap Therapeutics, Inc. | Conditions: Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies | Phase 1 | Status: COMPLETED